Accurate blood glucose monitoring is critical for diabetes patients to tightly control their diseases. For decades, blood glucose monitoring technology has relied on the use of reagents, including enzymes, mediators, and buffers. This monitoring technology not only is prone to interference and instability of the reagent. The daily use of multiple glucose test strips or implantable glucose sensors has been a great burden to the country. We have developed a biomimetic sensor utilizing nanopore structures that does not use any reagent and is free from interference commonly encountered in the conventional blood glucose monitoring devices (E. Chen, Novel Nanopore Structured Electrochemical Biosensor US Patent 11785,660, October 2, 2008). This report is to present current progress in the study of interference, which is an important step towards prototyping. D (+) xylose, D(+) galactose, ascorbic acid and uric acid were studied using the FDA approved protocols and were shown to exhibit negligible interferences (errors in the range of 1-3%). The evaluation results of the accuracy and linearity study using whole blood, serum and the standard reference materials are also presented. When compared to a method that is traceable to NIST’s standard, all test samples gave results within 5% of the reference value.
Journal: TechConnect Briefs
Volume: 3, Nanotechnology 2011: Bio Sensors, Instruments, Medical, Environment and Energy
Published: June 13, 2011
Pages: 101 - 104
Industry sectors: Medical & Biotech | Sensors, MEMS, Electronics
Topics: Chemical, Physical & Bio-Sensors, Diagnostics & Bioimaging